FDA puts hold on GenVec TNFerade
This article was originally published in Pharmaceutical Approvals Monthly
GenVec's gene-based oncologicTNFerade is on clinical hold after a possible increased risk of blood clots is seen in interim results of a Phase II esophageal cancer study. In the 24-patient trial, three of eight patients receiving the highest dose developed pulmonary embolism, one of whom died. Investigators judged the death "possibly related to TNFerade and underlying disease." The interim data were presented Oct. 1 at the European Organization for Research & Treatment of Cancer meeting in Geneva, Switzerland. GenVec plans to provide FDA with additional data, the firm said Oct. 7. In addition to esophageal cancer, GenVec's Phase II TNFerade program is looking at locally advanced pancreatic and rectal cancers...
You may also be interested in...
DuPont says it and P&G “have conducted extensive research on human commensals bacteria to help address metabolic health issues in humans.” The partnership "will help us further advance our probiotic innovation via a next generation solution that will prove beneficial to the health and well-being of consumers around the world,” says Paul Gama, P&G personal health care president.
Head & Shoulders airing a 30-second TV spot featuring Kansas City Chiefs quarterback Patrick Mahomes and former Pittsburgh Steelers safety Troy Polamalu competing over who gives “100%” effort in everything they do.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.